When Craig Sinclair told his wife he did not want to die in a hospital, the couple faced a challenge that extended beyond his advanced cancer diagnosis. Fulfilling his wish to spend his final days at home required navigating a complex healthcare system and securing tens of thousands of dollars in care that was not fully covered by insurance or public programs.

Sinclair, a British-born academic who moved to the United States in his twenties to pursue doctoral studies in comparative literature, died from bladder cancer on March 10, 2025, in the Brooklyn apartment he shared with his wife, Shannon Carroll. He was 49. Carroll was 37.His death came after more than two years of cancer treatment and several hospitalizations. It also followed a frantic effort by family and friends to raise more than $65,000 to cover private nursing care and medical supplies needed to support home hospice services.

The experience highlights broader questions about access to end-of-life care in the United States, where patients and families often face significant financial and logistical barriers when seeking alternatives to hospital-based care.By December 2024, Sinclair and Carroll had become familiar with New York City’s hospital system after multiple emergency admissions during the year.

During what would become Sinclair’s final hospitalization at NYU Langone Hospital in Manhattan, his condition had deteriorated significantly.According to Carroll, Sinclair became distressed after being transferred from intensive care to a shared room. The environment contrasted sharply with the comfort and familiarity of home, where he hoped to spend his remaining time.

Medical staff informed the couple that further treatment options had been exhausted and recommended hospice care. However, returning home required arrangements that extended beyond standard hospice services.

The hospital would only approve Sinclair’s discharge if adequate care could be provided in the apartment. While hospice services were available, they included limited nursing visits and were insufficient to address the complexity of Sinclair’s medical needs.A private nursing service was required to provide specialized wound care and daily medical support.

The service cost between $5,000 and $7,000 per week and included several hours of care each day from a registered nurse. The expenses quickly exceeded the couple’s financial resources.Carroll said she spent hours coordinating between healthcare providers, hospice representatives and private nursing companies while seeking approval for Sinclair’s discharge.

Eventually, medical staff agreed to allow him to return home after Carroll committed to providing around-the-clock support and securing funding for the additional care.Once back in Brooklyn, Sinclair’s condition appeared to improve emotionally. Carroll said the change in environment was immediate.

Surrounded by familiar possessions, preferred lighting and music, he was able to engage in longer conversations and spend meaningful time with family and friends.The experience reinforced the couple’s determination to maintain home-based care despite mounting costs.

To cover expenses, Carroll and her support network launched a fundraising effort. The money raised ultimately paid for private nursing services and medical equipment, but financial pressures persisted throughout Sinclair’s final months.The burden was compounded by limitations in existing caregiving support programs.

Carroll discovered that under New York law, spouses are not eligible to receive compensation through the state’s consumer-directed Medicaid caregiving program, even though other family members and non-relatives may qualify under certain circumstances.

As a result, Carroll spent months providing extensive care while also managing medical appointments, medications and administrative responsibilities without compensation.The financial strain extended beyond direct caregiving costs. Medical bills from previous hospital visits continued to arrive during and after Sinclair’s final illness.

Carroll said she received repeated notices regarding disputed charges, including a hospital bill of nearly $6,000 and a separate laboratory charge dating back more than a year.The couple also explored whether medical aid in dying could provide another option for Sinclair as his condition worsened.

During a chemotherapy appointment in 2024, Sinclair discussed the possibility with his oncologist. According to Carroll, the physician expressed support and noted that another patient had previously used medical aid in dying laws in a neighboring state.

At the time, however, Sinclair was unable to pursue that option. New Jersey’s residency requirements prevented him from qualifying there, while traveling to Vermont would have required a lengthy journey that his deteriorating health made impractical.The issue took on added significance after his death.In 2025, New York became the 13th U.S. state to approve medical aid in dying legislation.

The law is scheduled to take effect on August 5, 2026, allowing eligible terminally ill adults to request medication to end their lives under specific legal and medical conditions.According to Carroll, Sinclair would likely have qualified had the law been available during his final months.

For the family, however, the primary objective remained ensuring that Sinclair could spend his final days where he felt most comfortable.Even as his physical condition declined, Carroll recalled moments that reflected his personality and resilience. Friends, nurses and doctors frequently remarked on his humor.

During one hospital stay, despite significant weakness, he continued joking with staff members and expressing gratitude for those caring for him.At home, he remained engaged with news, music and conversations with loved ones for as long as his health allowed.

Carroll improvised practical solutions to help him maintain independence, including building a simple phone support stand so he could continue reading and communicating despite severe physical limitations.Following Sinclair’s death, Carroll remained in the apartment for several months before eventually moving out.

Among the final items she packed was a stair-assist cane used during his illness.For Carroll, the object served as a reminder not only of Sinclair’s final journey but also of the challenges many families face when attempting to honor a loved one’s wishes at the end of life.His death at home fulfilled a goal the couple had fought to achieve for months.

Achieving it, however, required substantial fundraising, unpaid caregiving and extensive coordination within a healthcare system where end-of-life choices often carry significant financial consequences.

When Maureen Sideris was treated for colon cancer in 2008, her recovery followed the traditional and often physically demanding path of surgery and post-operative rehabilitation. The treatment was successful, but the process was long and exhausting.

Fourteen years later, when the 71-year-old New York resident was diagnosed with oesophageal cancer, her treatment took a markedly different form. Instead of surgery, chemotherapy or radiation, she enrolled in a clinical trial at Memorial Sloan Kettering Cancer Center and began receiving infusions of the immunotherapy drug Dostarlimab every three weeks.

Each session lasted about 45 minutes. After four months, her tumour had disappeared.Sideris says the result felt almost unreal. Apart from adrenal insufficiency that causes fatigue, she experienced few major side effects. “It’s unbelievable,” she said. “It’s almost like science fiction.”Her case reflects a broader shift underway in oncology, where immunotherapy a treatment strategy designed to help the body’s own immune system recognize and destroy cancer cells is increasingly moving from experimental promise to routine clinical application.

After decades of research, oncologists say immunotherapy is now producing long-term remission and, in some cases, functional cures for patients who previously faced invasive surgery or limited treatment options.“I get choked up and have goosebumps,” said Jennifer Wargo, a professor of surgical oncology and immunotherapy researcher at MD Anderson Cancer Center.

“People are living, and living with good quality lives. We’re talking about cures.”The science behind immunotherapy is based on a relatively simple principle. The immune system is naturally designed to identify and eliminate cells that appear foreign or abnormal, including cells that become cancerous.

Karen Knudsen, chief executive of the Parker Institute for Cancer Immunotherapy, said the body is normally able to detect and remove cells that look like they do not belong. But cancer can evade that surveillance by making itself appear indistinguishable from surrounding healthy tissue.

Immunotherapy aims to reverse that concealment by helping the immune system identify cancer for what it is and launch a targeted response.Two of the most established forms of immunotherapy today are CAR T-cell therapy and immune checkpoint inhibitors.CAR T-cell therapy involves removing T cells the immune cells responsible for targeting specific threats from a patient’s blood, modifying them in a laboratory so they can better detect cancer, and then returning them to the body.

These therapies are currently used primarily for blood cancers.Immune checkpoint inhibitors work differently. They disable one of the immune system’s built-in “off switches,” mechanisms that normally prevent excessive immune responses from damaging healthy tissue.

Some cancer cells exploit these off switches, effectively telling immune cells not to attack. Checkpoint inhibitors prevent that signal, allowing T cells to identify tumours as threats and respond accordingly.

The significance of this approach was recognized globally when the scientists behind checkpoint inhibitor research were awarded the Nobel Prize in Physiology or Medicine 2018. These drugs are now used across multiple cancer types.However, both approaches have limitations.

Researchers have struggled to make CAR T-cell therapies consistently effective against solid tumours, which account for more than 90% of new cancer diagnoses. The treatment is also expensive and logistically complex because it requires individualized cell engineering.Checkpoint inhibitors can be easier to administer, but they carry risks.

Samra Turajlic, a medical oncologist at the Francis Crick Institute, described the side effects as a “kaleidoscope,” reflecting how broadly the immune system can react once normal regulatory controls are reduced.

Because these drugs remove safeguards meant to prevent the body from attacking itself, patients may experience immune-related complications involving healthy organs as well as tumours.

According to the National Cancer Institute, common side effects include fatigue, diarrhoea and skin rashes, while rare complications can involve inflammation of the liver, kidneys and heart.

Even when side effects are manageable, the larger problem is inconsistency.Turajlic said no immunotherapy works for all patients. Response depends on multiple factors, including the structure of the tumour, how accessible it is to immune cells, and the biological characteristics of the patient’s own immune system.

Current estimates suggest only 20% to 40% of patients respond meaningfully to immunotherapy, meaning many undergo treatment, side effects and emotional strain without clear benefit.That gap has pushed researchers toward combination strategies and more personalized approaches.Wargo’s early research suggests patients who follow high-fibre diets may improve treatment response through changes in the gut microbiome, which can influence both immune behavior and tumour biology.

Other studies indicate that statins, commonly prescribed cholesterol-lowering drugs, may unexpectedly enhance immunotherapy by altering cellular communication pathways.Timing may also matter. Some recent findings suggest patients treated earlier in the day may respond better than those receiving therapy later, raising new questions about how biological rhythms influence cancer care.

Combining immunotherapy with radiation or ultrasound is another area of active research.Sandra Demaria of Weill Cornell Medical Center said radiation can make tumours more visible to the immune system by changing how cancer cells present themselves. Ultrasound therapy, which uses high-frequency sound waves to target tumours, may have similar effects.

For many researchers, however, the most important shift is not simply adding more treatments, but identifying which patients are most likely to benefit from specific therapies.“We can now move toward treating not the cancer, but actually the patient,” Demaria said.Knudsen said that approach is especially important because cancer is not a single disease.

Oncology encompasses hundreds of biologically distinct conditions, and even patients with the same diagnosis may have profoundly different disease behavior at the cellular level.That principle is already shaping clinical practice at Memorial Sloan Kettering.

Researchers there identified that tumours carrying a specific genetic signature respond especially well to checkpoint inhibitors such as dostarlimab. In small clinical trials conducted in 2022 and 2024, patients with rectal cancers carrying that profile saw complete tumour eradication.

The institution later expanded the study to 117 patients with different cancers including oesophageal, bladder and stomach tumours that shared the same genetic marker.

Among the 103 patients who completed the full course of treatment, 84 experienced complete disappearance of their tumours. Only two required additional surgery.

Sideris was among those patients.

Her case illustrates how immunotherapy is changing expectations around cancer treatment. What once required major surgery can, for a growing subset of patients, now be addressed through carefully targeted immune intervention.Researchers caution that such outcomes remain highly dependent on tumour biology and patient selection, and they do not apply universally.

But the progress has changed how many oncologists view the future of cancer care less focused on destroying tumours through increasingly aggressive intervention, and more centered on teaching the body to do the work itself.